Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Johnathan Yap
Research Area(s) / Expertise:

Coronary Interventions

Coronary Physiology

 Job title: Consultant Cardiologist
Clinical Associate Professor Jonathan Yap is a Consultant with the Department of Cardiology at NHCS. His subspeciality interest is in interventional cardiology, pulmonary hypertension and structural heart disease including transcatheter aortic valve interventions (TAVI) for aortic stenosis. He spent a year in the United States performing his advanced fellowship in structural heart interventions… View more
Foreword

Article

Author(s): W Douglas Weaver Added: 3 years ago
As we enter 2008, many diverse influences are acting on cardiologists, tugging us in multiple directions. First, we still do not know whether we will be the object of a 10% reimbursement reduction from Medicare. In addition, there may be additional cuts for imaging, as the costs for such have increased greatly over the past few years and are not sustainable at the current annual increase in… View more

MI/ACS
Author(s): Shanmugam Uthamalingam , James L Januzzi Added: 3 years ago
Several cardiac biomarkers may aid in the diagnostic and prognostic evaluation of acute and chronic heart failure. In this article we discuss more novel and emerging applications of such established cardiac biomarkers in heart failure and review emerging data for several other promising markers. Novel Applications of Established Cardiac Biomarkers—Natriuretic Peptides B-type natriuretic peptide… View more

Heart Failure

MI/ACS
Author(s): Shubhayan Sanatani Added: 3 years ago
In children and young adults, sudden cardiac death (SCD) occurs in approximately 1-2 per 100,000 population.1,2 While the overwhelming majority of occurrences of SCD occur in the adult population and are due to ischemic heart disease, very few cases in a pediatric population are. Pediatric SCD is a relatively uncommon occurrence whose underlying etiology often remains elusive. A long list of… View more

Heart Failure
Author(s): James A Reiffel Added: 3 years ago
Atrial fibrillation (AF) is the most common sustained, medically significant, and troublesome arrhythmia encountered in clinical practice. AF has been associated with decreased quality of life (symptoms), serious morbidity (thromboemboli and tachycardia-induced cardiomyopathy), and increased risk of mortality. Several articles1,2 have reviewed this arrthymia in depth including its presentations,… View more

Electrophysiology & Arrhythmia
Author(s): Oussama M Wazni , Allan L Klein Added: 3 years ago
Atrial fibrillation (AF) is the most commonly sustained arrhythmia with a prevalence of 0.4% in the general population1-4 affecting 2.3 million people in the US.5 The prevalence increases with age being <1% in persons younger than 60 years of age to >8% in those older than 80 years.1,5-8 The incidence ranges from 0.2% per year for men 30 to 39 years of age to 2.3% per year in men 80 to 89… View more

Imaging & Diagnostics
Author(s): James L Januzzi Added: 3 years ago
The use of natriuretic peptide testing has dramatically risen recently, in recognition of the value of these blood tests for assisting in the evaluation of patients with suspected heart failure (HF). B-type natriuretic peptide (BNP) is formed as a consequence of production of a 108-amino-acid precursor peptide that is synthesised within the cardiomyocyte; this 'pro-BNP108' is subsequently cleaved… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): James L Januzzi Added: 3 years ago
The use of natriuretic peptide testing has dramatically risen recently, in recognition of the value of these blood tests for assisting in the evaluation of patients with suspected heart failure (HF). B-type natriuretic peptide (BNP) is formed as a consequence of production of a 108-amino-acid precursor peptide that is synthesised within the cardiomyocyte; this 'pro-BNP108' is subsequently cleaved… View more

Imaging & Diagnostics

Heart Failure
Author(s): Rahul Sakhuja , James L Januzzi Added: 3 years ago
Introduction With nearly 500,000 new cases per year and direct costs estimated as high as US$38 billion annually, congestive heart failure (CHF) has become a major priority in modern medicine. This crisis will continue to grow as the population ages, thus the discernment of new diagnostic and therapeutic strategies to improve prognosis and reduce costs is critical.1 The irony is that therapies… View more

Heart Failure
TCT 23: 5 Trials That Changed My Practice
Author(s): Kendra J Grubb Added: 5 months ago
TCT 23 - We are joined by Dr Kendra Grubb (Emory School of Medicine, Atlanta, GA, US) for a concise and insightful summary of the late-breaking trials that are expected to have an impact on interventional science concerning structural heart disease and clinical practice. Trials covered in detail include: PARTNER 3 & EVOLUT Low-Risk ALIGN-AR TENDYNE APOLLO TRILUMINATE Recorded remotely… View more

Intervention